Sidley represented the seller in connection with the placement of 14,500,000 existing shares of Alphamab Oncology (HKEX: 9966). The total transaction value is approximately HK$239.3 million (US$30 million). Morgan Stanley & Co. International plc acts as the sole placing agent of the transaction.
Alphamab Oncology is a leading clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in biospecifics and protein engineering.
In December 2019, Sidley acted as the Hong Kong and U.S. legal adviser in its initial public offering (IPO) on the Main Board of The Stock Exchange of Hong Kong, and has since been acting as its Hong Kong legal adviser in relation to the company’s post-listing regulatory work. In addition, Sidley also advised Alphamab Oncology on its Series A and Series B pre-IPO financings in December 2018 and May 2019 respectively, which highlighted Sidley’s comprehensive service capabilities. According to the most recent data compiled by Ryanben Capital, Sidley has again retained its position as the number one legal adviser in the Hong Kong IPO league table by deal volume in the past 24 months (June 2018 to May 2020).